Hematologics has assembled an in-house group of experts in each diagnostic field so that all testing is performed at Hematologics and not sent out to other specialty labs. This speeds up analysis and permits rapid response to unexpected findings due to communication between directors on every case.
Hematologics provides immunophenotyping, cytogenetics, fluorescence in situ hybridization, molecular analysis studies and microscopic examination in our own state-of-the-art flow cytometric, cytogenetic and molecular biology laboratories. Send us a sample, and we will provide full interpretive reports.
Small numbers of residual malignant cells are associated with clinical relapse at a later date. Hematologics is the leader in residual disease testing by flow cytometry using a Difference from Normal approach. We also offer a comprehensive menu of quantitative PCR assays for translocations, flow cytometric cell sorting, and molecular profiling by DNA analysis.
Hematologics has found that 30% of all cytopenias are associated with abnormal myeloid cells. With our unique Difference from Normal Flow Cytometric analysis, we assign an MDS Flow score that is associated with Myelodysplastic syndromes. We also offer aCGH/SNP microarray (LOH), FISH panels, cytogenetic karyotypes, and comprehensive DNA mutation panels
Hematologics combines plasma cell enrichment and plasma cell sorting for FISH and aCGH/SNP microarray analysis for the diagnosis, prognosis and monitoring of plasma cell neoplasms. For patients with concurrent monoclonal B-cell and plasma cell populations, we offer PCR IGH monoclonality profiling and MYD88 on the sorted populations to establish diagnosis.
Hematologics has extensive experience analyzing biopsies from patients on clinical trials, including those treated with novel therapies. Please contact us to find out more how we can help clinical trial monitoring or assessment of new drug targets for the treatment of myeloid or lymphoid neoplasms.